Canadian Company Groupe RSL Produces Canada’s First Lab-Grown Diamond Gem
20.9.2022 14:30:00 EEST | Business Wire | Press release
Groupe RSL is the first company to produce a Canadian lab-grown diamond gem, at its production facility in Quebec. The company is currently producing large diamonds for the premium jewellery market. With sustainability at the heart of its approach, Groupe RSL believes that lab diamonds have the potential to significantly reduce the environmental impacts of diamond production.
“Laboratory diamonds have the potential to revolutionize the industry, while reducing the environmental and human costs associated with diamond production,” said Luke Sinclair, CFO of Groupe RSL. “Consumers are seeking greater transparency in the diamonds that they purchase, and we firmly believe that the industry need not be at odds with the environment or principles of social responsibility. We are excited to see how the lab-grown diamond industry evolves over the coming years.”
Groupe RSL produces its diamonds locally in Quebec using a chemical vapour deposition, or CVD, process, whereby hydrogen and methane gas are combined in a plasma under precise conditions to grow diamonds one atom at a time over a period of several weeks to a month. Powered entirely by hydroelectricity, Groupe RSL has developed its own unique process to become the first Canadian company to use this approach to make diamond gems.
“For most of human scientific history, we thought that it was impossible to make diamonds in anything but the hottest high-pressure conditions. That’s why early attempts at man-made diamond focused on replicating the intense pressure that creates diamonds beneath the ground,” adds Sinclair. “Recent research has brought to light a new idea, using hydrogen and methane gas in a controlled reaction.”
Mined diamonds vs. lab-created diamonds
Mined diamonds and lab created diamonds are identical—chemically, physically and optically, and cannot be distinguished from one another without highly specialized equipment. In fact, mined diamonds often contain defects or impurities, both of which can be controlled or removed in lab diamonds.
Consumer shift
There has been a significant increase in demand for lab-grown diamonds in recent years, with lab diamond’s share of diamond sales more than doubling between 2020 and 2022.1 Millennials and Generation Z are moving away from mined diamonds, with nearly 70% of millennials considering buying a lab grown alternative.2 Consumers also seek greater transparency to ensure diamonds are sourced responsibly and produced sustainably. For example, nine in ten Generation Z consumers believe companies have a responsibility to address environmental and social issues.
About Groupe RSL Inc.
Groupe RSL Inc. is an innovative producer of diamond and the only Canadian producer of lab diamonds for the jewellery market. The company produces diamonds using a unique CVD process and technology. Groupe RSL produces beautiful and sustainable Canadian diamonds at its Quebec-based facility which is powered by 100% hydroelectricity. While their diamonds last forever, the company is committed to ensuring their ecological and social footprint does not. For more information, visit www.groupersl.com.
__________________________
1 Diamond industry analyst Edahn Golan. https://www.gemsociety.org/news/2022/05/18/interest-lab-grown-diamonds-surging-shows-no-signs-of-stopping/#:~:text=In%202020%2C%20lab%20diamond's%20share,be%20expected%2C%E2%80%9D%20said%20Golan
2 Millennial Consumer Research Lab Grown Diamonds, MVI Marketing LLC, May 3, 2018.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005008/en/
Contact information
Eric Aach
514-569-3594
eaach@national.ca
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
